New Screening Test Improves Detection of Prostate Cancer Using Circulating Tumor Cells and Prostate-Specific Markers

New Screening Test Improves Detection of Prostate Cancer Using Circulating Tumor Cells and Prostate-Specific Markers

The current screening-test for prostate cancer, affecting 10% of men worldwide, has a high false negative rate and a low true positive rate. A more reliable screening test is needed. Circulating-Tumor-Cells (CTC) provide a biomarker for early carcinogenesis, cancer progression and treatment effectiv...

Full description

Bibliographic Details
Main Authors:	Karin Ried, Tasnuva Tamanna, Sonja Matthews, Peter Eng, Avni Sali
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2020-04-01
Series:	Frontiers in Oncology
Subjects:	prostate cancer circulating tumor cells (CTC) prostate specific antigen (PSA) early detection cancer screening
Online Access:	https://www.frontiersin.org/article/10.3389/fonc.2020.00582/full

Similar Items

Controversies in Prostate Cancer Screening: is the Prostate Specific Antigen useful?
by: Pablo Yago Giménez, et al.
Published: (2019-12-01)

Prostate-Specific Antigen Trends Predict the Probability of Prostate Cancer in a Very Large U.S. Veterans Affairs Cohort
by: R. Jeffrey Karnes, et al.
Published: (2018-08-01)

Beyond prostate-specific antigen: alternatives for prostate neoplasm screening
by: Yu, Kevin Kuo-Han
Published: (2016)

PSA screening for prostate cancer
by: Marcus V. Sadi

Analysis of Circulating Tumor Cells in Patients with Non-Metastatic High-Risk Prostate Cancer before and after Radiotherapy Using Three Different Enumeration Assays
by: Joanna Budna-Tukan, et al.
Published: (2019-06-01)

Clinical Issues for Prostate-Specific Antigen Screening: A Narrative Review
by: Marco Randazzo, et al.
Published: (2018-12-01)

Prostate – Specific Antigen (Psa) as a Screening Tool for Benign Prostate Hyperplasia (Bph) and Prostate Cancer (Pca) in Sulaimani Province
by: Sirwan M. Muhammad, et al.
Published: (2013-09-01)

Population-based Prostate Cancer Screening in Kazakhstan
by: Yevgeniy ISHKININ, et al.
Published: (2017-06-01)

Kinetics of Prostate-Specific Antigen after Carbon Ion Radiotherapy for Prostate Cancer
by: Narisa Dewi Maulany Darwis, et al.
Published: (2020-03-01)

Prostate Cancer Screening with PSA: Ten Years’ Experience of Population Based Early Prostate Cancer Detection Programme in Lithuania
by: Ausvydas Patasius, et al.
Published: (2020-11-01)

Prostate cancer screening with prostate-specific antigen: A guide to the guidelines
by: Sonja Cabarkapa, et al.
Published: (2016-12-01)

Clinical Impact of Circulating Tumor Cells in Patients with Localized Prostate Cancer
by: Lucile Broncy, et al.
Published: (2019-07-01)

Diagnostic value of free-to-total PSA proportion and PSA density in prostate cancer detection for prostate volumes >= 100 cc
by: Murat Zor, et al.
Published: (2018-12-01)

Uptake of prostate cancer screening and associated factors among Chinese men aged 50 or more: a population-based survey
by: Winnie K. W. So, et al.
Published: (2014-03-01)

The Accuracy of Increased Blood Concentration of Prostate-Specific Antigen to Prostate Malignancy
by: Daniel Mahendra Krisna, et al.
Published: (2018-04-01)

Association between prostate specific antigen change over time and prostate cancer recurrence risk: a joint model
by: Reza Ali Mohammadpour, et al.
Published: (2020-05-01)

Assessment of harms, benefits, and cost‐effectiveness of prostate cancer screening: A micro‐simulation study of 230 scenarios
by: Abraham M. Getaneh, et al.
Published: (2020-10-01)

Prostate-specific antigen (PSA) and distress: - a cross-sectional nationwide survey in men with prostate cancer in Sweden
by: Ulrika Rönningås, et al.
Published: (2019-07-01)

Performance of PSA and of PSA density in the diagnosis of prostate carcinoma
by: Antonio Carlos Pereira Martins, et al.
Published: (2002-01-01)

The role of serum testosterone to prostate-specific antigen ratio as a predictor of prostate cancer risk
by: Cenk Gurbuz, et al.
Published: (2012-12-01)

Can Prostate Specific Antigen Be Used as New Biomarker for Early Diagnosis of Breast Cancer?
by: Seyed Mostafa Shiryazdi, et al.
Published: (2015-09-01)

Metastatic Prostate Cancer Diagnosed by Bone Marrow Aspiration in an Elderly Man Not Undergoing PSA Screening
by: Ridwan Alam, et al.
Published: (2017-02-01)

Diagnostic value of PCA3, TMPRSS2:ERG and prostatic specific antigen derivatives in the detection of prostate cancer
by: A. A. Musaelyan, et al.
Published: (2020-07-01)

Molecular Detection of Prostate Specific Antigen in Patients with Prostate Cancer or Benign Prostate Hyperplasia the First Investigation from Iran
by: L Andonian, et al.
Published: (2005-08-01)

Molecular Detection of Prostate Specific Antigen in Patients with Prostate Cancer or Benign Prostate Hyperplasia the First Investigation from Iran
by: L Andonian, et al.
Published: (2005-09-01)

CLINICAL SIGNIFICANSE OF PROSTATE-SPECIFIC ANTIGEN IN BREAST CANCER PATIENTS
by: N. S. Sergeeva, et al.
Published: (2020-12-01)

Importance of prostate-specific antigen (PSA) as a predictive factor for concordance between the Gleason scores of prostate biopsies and RADICAL prostatectomy specimens
by: Nelson Gianni de Lima, et al.
Published: (2013-06-01)

Characteristics of PSA Bounce after Radiotherapy for Prostate Cancer: A Meta-Analysis
by: Narisa Dewi Maulany Darwis, et al.
Published: (2020-08-01)

Toward Maximizing Immunotherapy in Metastatic Castration Resistant Prostate Cancer – Rationale for Combinatorial Approaches Using Chemotherapy
by: Susan F Slovin
Published: (2012-05-01)

The routine use of prostate-specific antigen for early detection of cancer prostate in India: Is it justified?
by: Deepak Dubey
Published: (2009-01-01)

Accuracy of Tumour-Associated Circulating Endothelial Cells as a Screening Biomarker for Clinically Significant Prostate Cancer
by: Sebastian Chakrit Bhakdi, et al.
Published: (2019-07-01)

Influence of Tumor Burden on Serum Prostate-Specific Antigen in Prostate Cancer Patients Undergoing Radical Prostatectomy
by: Philipp Mandel, et al.
Published: (2021-07-01)

What Is the Most Appropriate Test in Detecting Prostate Cancer in Patients With Intermediate Prostate Specific Antigen Levels?
by: Hassan Jafari, et al.
Published: (2009-02-01)

Impact on prostate cancer clinical presentation after non-screening policies at a tertiary-care medical center- a retrospective study
by: Tarek Ajami, et al.
Published: (2021-02-01)

The results of prostate cancer screening and the problem of the hyperdiagnosis of the disease in the Republic of Belarus
by: S. A. Krasnyi, et al.
Published: (2016-05-01)

The effect of green tea on prostate specific antigen (PSA): A systematic review and meta-analysis of randomized controlled trials
by: Elham Sharifi-Zahabi, et al.
Published: (2021-03-01)

Prospective investigation of change in the prostate-specific antigens after various urologic procedures
by: Park SC, et al.
Published: (2015-07-01)

Investigation of correlations between different prostate-specific antigen forms and clinical and morphological characteristics of a tumor process in patients with prostate cancer
by: N. S. Sergeeva, et al.
Published: (2015-06-01)

Bone scintigraphy in staging of newly diagnosed prostate cancer in regard of different risk groups
by: Sabina Sevcenco, et al.
Published: (2019-06-01)

The Current Status of Prostate Cancer*
by: Mukund S. Joshi
Published: (2018-10-01)